Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
Want to see IN:LAURUSLABS full AI Analyst Report?
Top Page
Laurus Labs Ltd.
(LAURUSLABS)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹1,211.00
▲(9.39% Upside)
Action:ReiteratedDate:10/29/25
Laurus Labs' overall stock score is driven by strong technical momentum, despite overbought signals, and solid financial performance with revenue growth. However, high valuation metrics and cash flow challenges weigh on the score.
Positive Factors
Revenue Growth
Sustained ~27% revenue growth indicates expanding commercial traction across APIs, FDF and CDMO lines. Given Laurus's global supply footprint and ARV exposure, this top-line momentum supports scale economics, reinvestment capacity and long-term contract credibility over months.
Negative Factors
Negative Free Cash Flow
Negative free cash flow driven by elevated capex constrains internal funding for operations or dividends and increases reliance on external financing. Persistent negative FCF can pressure liquidity and limit strategic flexibility across the next 2–6 months if capex remains high.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~27% revenue growth indicates expanding commercial traction across APIs, FDF and CDMO lines. Given Laurus's global supply footprint and ARV exposure, this top-line momentum supports scale economics, reinvestment capacity and long-term contract credibility over months.
Read all positive factors
Laurus Labs Ltd. (LAURUSLABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹601.13B
Dividend Yield0.15%
Average Volume (3M)107.31K
Price to Earnings (P/E)59.4
Beta (1Y)1.03
Revenue Growth27.46%
EPS Growth320.69%
CountryIN
Employees6,007
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.70
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.23
Price to Sales (P/S)5.82
P/FCF Ratio-821.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,280.00Price Target Upside15.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.64
Revenue Forecast (FY)₹78.90B
Laurus Labs Ltd. Business Overview & Revenue Model
Company Description
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and a...
How the Company Makes Money
Laurus Labs primarily makes money by manufacturing and selling (1) active pharmaceutical ingredients (APIs) and (2) finished dosage formulations (FDF), along with (3) contract development and manufacturing services for other companies.
1) APIs (A...
Laurus Labs Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.58B | 55.54B | 50.41B | 60.41B | 49.36B | 48.14B |
| Gross Profit | 32.18B | 29.65B | 25.01B | 31.81B | 26.87B | 26.14B |
| EBITDA | 14.81B | 10.34B | 7.63B | 16.06B | 14.18B | 15.50B |
| Net Income | 6.84B | 3.58B | 1.61B | 7.90B | 8.28B | 9.84B |
Balance Sheet | ||||||
| Total Assets | 94.15B | 93.36B | 83.87B | 76.60B | 69.68B | 57.51B |
| Cash, Cash Equivalents and Short-Term Investments | 633.80M | 1.44B | 1.42B | 484.60M | 759.40M | 484.60M |
| Total Debt | 22.12B | 27.64B | 25.77B | 20.15B | 17.77B | 14.82B |
| Total Liabilities | 44.82B | 47.33B | 42.71B | 36.12B | 36.09B | 31.50B |
| Stockholders Equity | 48.05B | 44.73B | 41.11B | 40.38B | 33.51B | 25.98B |
Cash Flow | ||||||
| Free Cash Flow | 6.04B | -393.50M | -126.20M | 37.40M | 342.60M | 442.30M |
| Operating Cash Flow | 10.93B | 6.02B | 6.66B | 9.94B | 9.11B | 7.33B |
| Investing Cash Flow | -4.77B | -6.82B | -8.22B | -9.96B | -9.14B | -9.41B |
| Financing Cash Flow | -6.68B | 392.80M | 2.50B | -266.40M | 302.60M | 2.55B |
Laurus Labs Ltd. Technical Analysis
Positive
1107.05
Price Trends
1025.73
Positive
1031.18
Positive
951.58
Positive
Market Momentum
28.59
Negative
67.71
Neutral
95.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LAURUSLABS, the sentiment is Positive. The current price of 1107.05 is above the 20-day moving average (MA) of 1039.84, above the 50-day MA of 1025.73, and above the 200-day MA of 951.58, indicating a bullish trend. The MACD of 28.59 indicates Negative momentum. The RSI at 67.71 is Neutral, neither overbought nor oversold. The STOCH value of 95.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LAURUSLABS.
Laurus Labs Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹1.69T | 72.71 | ― | 0.46% | 13.62% | 19.93% | |
74 Outperform | ₹821.14B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
72 Outperform | ₹1.10T | 21.88 | ― | 0.63% | 11.01% | 5.28% | |
72 Outperform | ₹1.05T | 20.49 | ― | 0.57% | 18.86% | 61.69% | |
71 Outperform | ₹3.89T | 30.62 | ― | 0.91% | 10.09% | -4.53% | |
66 Neutral | ₹601.13B | 59.42 | ― | 0.15% | 27.46% | 320.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LAURUSLABS
Laurus Labs Ltd.
1,123.85
507.45
82.32%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,417.65
212.48
17.63%
IN:DIVISLAB
Divi's Laboratories Limited
6,475.35
391.15
6.43%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,334.55
165.71
14.18%
IN:LUPIN
Lupin Limited
2,324.25
269.62
13.12%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,733.80
-53.47
-2.99%
Laurus Labs Ltd. Corporate Events
Laurus Labs Closes Trading Window Ahead of FY26 Results
Mar 30, 2026
Laurus Labs Limited has announced that its trading window for dealing in the company’s securities will be closed from April 1, 2026, until 48 hours after the declaration of its audited financial results for the quarter and year ended March 3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.